Related Experiment Videos
Subarachnoid buprenorphine administered by implantable micropumps
N Francaviglia1, C Silvestro, F Carta
1Clinica Neurochirurgica, Università di Genova, Italy.
Acta Neurochirurgica
|January 1, 1990
Summary
Subarachnoid buprenorphine effectively managed severe pain in 23 cancer patients, improving quality of life without respiratory depression or tolerance. This treatment offers a safe and viable option for intractable cancer-related pain.
Area of Science:
- Oncology
- Pain Management
- Neurosurgery
Background:
- Cancer patients often experience severe, intractable pain, particularly low back and chest pain.
- Chest, urological, and gynecological cancers are common causes of such debilitating pain.
- Effective pain management is crucial for improving the quality of life in advanced cancer patients.
Purpose of the Study:
- To evaluate the efficacy and safety of subarachnoid buprenorphine for managing cancer-related pain.
- To assess the impact of subarachnoid buprenorphine on patients' quality of life.
- To determine the incidence of adverse effects, such as respiratory depression and tolerance.
Main Methods:
- Treatment involved 23 patients with cancer-related low back and chest pain.
- Subarachnoid buprenorphine was administered via single bolus or slow infusion using micropumps.
- Daily doses were adjusted based on individual patient needs, ranging from 0.06-0.15 mg.
Main Results:
- Successful pain control was achieved in all treated patients.
- Patients reported a significant improvement in their quality of life, enabling near-normal daily activities.
- No instances of respiratory depression or drug tolerance were observed during the treatment period.
Conclusions:
- Subarachnoid buprenorphine is a highly effective and safe treatment for severe cancer-related pain.
- This method offers a promising alternative for patients with intractable pain unresponsive to other therapies.
- The absence of respiratory depression and tolerance highlights its favorable safety profile.